pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference
BOSTON, Sep 09, 2010 (BUSINESS WIRE) -- pSivida Corp, (NASDAQ:PSDV)(ASX:PSD), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, Monday, September 13. Dr. Paul Ashton, President and Chief Executive Officer of pSivida, will present at 2:00 p.m. Eastern time.
A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/rrshq18/psdv as well as at the company's website: http://www.psivida.com. A replay of the presentation will be available at the company's website for 90 days.
The company recently announced that the FDA has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien®, its drug for diabetic macular edema that has been licensed to Alimera Sciences. As a result, pSivida believes that a response from the FDA regarding Iluvien could be received in the fourth quarter of this year. Approval of Iluvien would trigger a $25 million milestone payment to pSivida from Alimera and under the license agreement, pSivida also receives 20 percent of net profits on sales of Iluvien by Alimera.
About pSivida Corp.
pSivida Corp is a world leader in the development of tiny, sustained release, drug delivery products and technologies that are administered by implantation, insertion or injection. The Company uses these systems to develop treatments for serious, unmet, medical needs. pSivida's intellectual property portfolio consists of over 50 patent families, more than 100 granted patents, including patents accepted for issuance, and more than 150 patent applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: maintaining collaboration agreements with Alimera and Pfizer; modifications of existing terms of collaboration agreements with Alimera and Pfizer; achievement of milestones and other contingent contractual events; ability to prove safety and efficacy of, and achieve regulatory approvals for, and successfully commercialize Iluvien, BrachySil and other products;; ability to raise capital; ability to achieve profitability; ability to derive revenues from Retisert; ability to develop new products; impairment of intangibles; fluctuations in the fair values of certain outstanding warrants; fluctuations in operating results; termination of license agreements; ability to obtain partners to develop and market products; competition; extent of third-party reimbursement for products; product liability; ability to protect intellectual property or infringement of others' intellectual property; retention of key personnel; consolidation in the pharmaceutical and biotechnology industries; compliance with laws; maintaining effective internal control over financial reporting; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution through exercise of outstanding warrants and stock options or future stock issuances; possible influence by Pfizer; ability to pay any registration penalties; and other factors described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
SOURCE: pSivida Corp.
US Contact:
Martin E. Janis & Company, Inc.
Beverly Jedynak, President
312-943-1123
bjedynak@janispr.com
or
Australia Contact:
pSivida Corp.
Brian Leedman, Vice President, Investor Relations
+61 8 9227 8327
brianl@psivida.com
